Background: Tamoxifen has been US Food and Drug Administration-approved for primary prevention of breast cancer since 1998 but has not been widely adopted, in part because of increased risk of serious side effects. Little is known about the risk-benefit profiles of women who use chemoprevention outside of a clinical trial. We examined characteristics associated with initiation and discontinuation of tamoxifen for primary prevention of breast cancer within a large cohort of women with a first-degree family history of breast cancer.
article primary breast cancer that encourages clinicians to offer to prescribe tamoxifen or raloxifene to reduce breast cancer risk (8) . National estimates indicate that less than 1% of eligible women use tamoxifen for prevention (9) . It is unknown why few women use tamoxifen for breast cancer prevention, although vasomotor symptoms, increased risk of adverse health effects, and difficulties in estimating or communicating risk-benefit profiles can be deterrents.
Whether women who do use tamoxifen for breast cancer prevention are among those most likely to benefit is also unknown. In previous studies, willingness to use tamoxifen has not consistently been associated with invasive breast cancer risk (10) (11) (12) (13) . Further, substantial nonadherence to the recommended five-year course of tamoxifen has been reported in prevention trials. To date, there has been no large study of tamoxifen users outside of a trial setting to evaluate risk-benefit profiles or early discontinuation.
We examined risk-benefit profiles of women who used tamoxifen for primary breast cancer prevention and characteristics associated with initiation and discontinuation among a sample of adult US and Puerto Rican women with a first-degree family history of breast cancer.
Methods
The Sister Study prospective cohort was designed to address genetic and environmental risk factors for breast cancer. From 2003 to 2009, 50 884 US and Puerto Rican women age 35 to 74 years were recruited through a national multimedia campaign and network of recruitment volunteers, breast cancer professionals, and advocates. Eligible women had a sister who had been diagnosed with breast cancer but did not have breast cancer themselves. Participants completed baseline computerassisted telephone interviews on medical and family history, lifestyle factors, and demographics. All participants were asked, "Have you ever used tamoxifen or Nolvadex (these are taken to prevent breast cancer)?" at enrollment and reported ages they started and/or stopped using tamoxifen and their total duration of use. All participants provided informed consent. This research was approved by the Institutional Review Boards of the National Institute of Environmental Health Sciences, the National Institutes of Health, and the Copernicus Group.
Study Design
We identified 1046 women who reported ever using tamoxifen ("tamoxifen users") at enrollment. Of these, 1038 women provided information on the age they started and stopped using tamoxifen. For comparison subjects, we randomly selected up to four women from the cohort who reported never using tamoxifen ("nonusers") matched on age and year of enrollment to each tamoxifen user. An index age was defined as the age of tamoxifen initiation for each user and the corresponding age for her matched control patients. The index age allowed for comparisons between tamoxifen users and nonusers to be made relative to the time of tamoxifen initiation, rather than at enrollment when tamoxifen use could have influenced participant characteristics (eg, postmenopausal hormone use, hysterectomy status, etc.).
We excluded women with a history of contraindicating medical conditions as of the index age (n = 52, including 41 cataract, one stroke, five transient ischemic attack [TIA] , four uterine cancer, one combination TIA, stroke, and cataract) or who participated in a clinical trial of tamoxifen (n = 173). Twenty-five women were excluded because of a diagnosis of lobular carcinoma in situ that preceded tamoxifen use or missing date of breast cancer diagnosis. In total, 788 women contributed information as tamoxifen users, of which 767 were matched with four nonusers and 21 matched with three (n = 3131) nonusers.
Participant Characteristics
Characteristics defined prior to the index age included smoking, hysterectomy, oophorectomy, menopausal status, postmenopausal hormone use, and raloxifene use. Characteristics at enrollment included demographics, general health, breast biopsy history, and BRCA1/2 testing. We calculated a five-year probability of developing invasive breast cancer with the SAS macro for the Breast Cancer Risk Assessment Tool (BCRAT) designed by the National Cancer Institute and the National Surgical Adjuvant Breast and Bowel Project (14) (15) (16) (17) (18) (19) , which uses information on age, age at menarche, nulliparity or age at first live birth, first-degree family history of breast cancer, breast biopsy history, and race/ethnicity (http://www.cancer.gov/ bcrisktool/).
Risk-Benefit Estimates
We categorized women according to a risk-benefit index proposed by Gail et al. (16) and recently updated by Freedman et al. (20) that is recommended for patient counseling by the USPSTF (8) and the National Comprehensive Cancer Network (NCCN) (21) . Briefly, the risk-benefit index classifies women according to the level of evidence (none, moderate, strong) for tamoxifen benefits (breast cancer and fracture prevention) to exceed the risk of serious side effects (endometrial cancer, stroke, pulmonary embolism, deep vein thrombosis, and cataract) using age, five-year projected risk of invasive breast cancer, hysterectomy, and race. Detailed information on the construction of the index has been published (16, 20) . In our analysis, we used index age, hysterectomy status at index age, and five-year probability of invasive breast cancer risk calculated using age at enrollment because of a lack of age-specific information on breast biopsy history.
Among the 788 tamoxifen users, we characterized the riskbenefit index for 742 (94%) women. In our sample, 131 women had a BCRAT score greater than or equal to 7.5% which exceeds the highest listed BCRAT category (7.0%). For analysis, these women were included in the 7.0% BCRAT category to preserve the maximum sample size; results were largely unchanged when they were alternatively excluded from analysis. Risk-benefit categories were not defined for 46 tamoxifen users for the following reasons: Categories have not been defined for Hispanic women younger than 50 years (n = 10), other race-ethnicities (n = 18), BCRAT scores of less than 1.5% (n = 12), or ages younger than 35 years (n = 1). Finally, scores could not be calculated for five women missing components of the index.
Statistical Analysis
Odds ratios and 95% confidence intervals for characteristics associated with tamoxifen use were calculated with multivariable conditional logistic regression to account for the matched design. In analyses of tamoxifen users only, unconditional logistic regression was applied. Two-sided P values of less than or equal to .05 were considered to be statistically significant. Kaplan-Meier curves were produced to display article tamoxifen discontinuation over five years with Stata 12 software (StataCorp., College Station, TX) (22) . All other statistical analyses were performed with SAS 9.3 (SAS Institute, Inc., Cary, NC).
Sensitivity Analyses
Sister Study eligibility precluded previous breast cancer diagnosis. Women with higher BCRAT scores and correspondingly favorable risk-benefit indices at the index age may have been disproportionately ineligible to participate if they developed breast cancer in the intervening years. Therefore, we performed sensitivity analyses to evaluate associations with the BCRAT score and risk-benefit index among tamoxifen users who began use within five years (n = 363) and two years (n = 120) of study enrollment and their matched nonusers (n = 1443 and n = 475, respectively).
BCRAT scores were calculated for age at study enrollment rather than tamoxifen initiation. To evaluate the sensitivity of results to possible changes in BCRAT score between these ages, we restricted the evaluation of the risk-benefit index to current tamoxifen users (n = 272) for whom the interval between tamoxifen initiation and study enrollment (mean = 2.6 years, SD = 1.9, IQR = 1-4) was shorter. Risk-benefit index categories were defined for 95% of this subgroup (n = 258).
Results
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Among tamoxifen users, the mean age at tamoxifen initiation was 50.7 years (SD = 7.4). The median calendar year of tamoxifen initiation was 2001; the mode was 2000. Overall, 74% of classified tamoxifen users had a favorable (defined as moderate to strong evidence for benefits to exceed risks) risk-benefit profile and 20% had no evidence that the benefits exceeded risks ( Figure 1) ; the risk-benefit index could not be calculated for 6%. The riskbenefit index distribution across calendar years is provided in Supplementary Table 1 (available online) .
When stratified by factors contributing to the risk-benefit score (eg, hysterectomy, race, age), the proportion with insufficient evidence of net benefit varied between groups. Women who had hysterectomies prior to starting tamoxifen were 11 times more likely to have a favorable risk-benefit profile compared with women with an intact uterus (OR = 11.87, 95% CI = 5.94 to 23.73). Younger women were likely to have a favorable risk-benefit index; only three of the 321 women who started tamoxifen before age 50 years had no evidence of benefit. Compared with non-Hispanic whites, the 28 African American women were 65% less likely to have a favorable risk-benefit profile (OR = 0.35, 95% CI = 0.16 to 0.75) ( Figure 1 ). These patterns were also apparent in sensitivity analyses restricted to current users (Supplementary Figure 1 , available online).
More than 90% of tamoxifen users were non-Hispanic white. African American and Hispanic women were 48% to 59% less likely compared with Non-Hispanic white women to report use (OR = 0.41, 95% CI = 0.26 to 0.63 and OR = 0.52, 95% CI = 0.30 to 0.90, respectively) ( Table 1) . Tamoxifen users were 50% more likely to have had a hysterectomy prior to tamoxifen use (OR = 1.56, 95% CI = 1.21 to 2.01); however, the majority of users (66%) had an intact uterus at tamoxifen initiation. After accounting for hysterectomy status, bilateral oophorectomy did not contribute to odds of tamoxifen use, though women who reported using unopposed estrogens (the recommended formulation for women without a uterus) were less likely to use tamoxifen compared with never-users of postmenopausal hormones (OR = 0.70, 95% CI = 0.51 to 0.95). More extensive family histories of breast cancer and higher BCRAT scores were strongly related to odds of tamoxifen initiation. Five-and six-fold (16, 20) indicating no, moderate, or strong evidence that the benefits of tamoxifen for the primary prevention of breast cancer and fracture exceed the risk of serious side effects (ie, endometrial cancer, stroke, pulmonary embolism, deep vein thrombosis, and cataract). Percentages are shown overall and according to hysterectomy status, race, and age at tamoxifen initiation. B) Odds ratios (95% confidence intervals) for a favorable risk-benefit profile (moderate or strong evidence that benefits of tamoxifen outweigh the risks) according to hysterectomy status, race, and age at tamoxifen initiation. CI = confidence interval. article increases in tamoxifen use were observed among women with BCRAT scores of 3% to 6% (OR = 4.97, 95% CI = 3.57 to 6.24) or with more than one sister with breast cancer (OR = 6.53, 95% CI = 4.66 to 9.12). Tamoxifen users were also more likely to have moderate (OR = 1.64, 95% CI = 1.22 to 2.19) or strong (OR = 4.33, 95% CI = 3.27 to 5.74) evidence of benefit compared with nonusers. Women who reported having a breast biopsy were twice as likely to use tamoxifen compared with those with no biopsy article history (OR = 2.06, 95% CI = 1.65 to 2.56). Tamoxifen users were more likely to report worse general health, but were not more likely to smoke (Table 1) . Patterns with BCRAT scores persisted in analyses restricted to women with tamoxifen initiation within five or two years of enrollment (for whom risk scores calculated at enrollment were a better reflection of breast cancer risk at the time of tamoxifen initiation) (Supplementary Figure 2, available online) . In sensitivity analyses restricted to women with an index age within five years of study enrollment, tamoxifen associations with risk-benefit indices were attenuated but still apparent for moderate and strong evidence categories (OR = 1.41, 95% CI = 0.93 to 2.14 and OR = 3.21, 95% CI = 2.10 to 4.89, respectively) (data not shown).
Tamoxifen Discontinuation
At 4.5 years, 46% of tamoxifen users had discontinued use (Figure 2) . Among former users, the median duration of tamoxifen use was 3.0 years. Women who reported using raloxifene after tamoxifen were 55% less likely to complete five years (OR = 0.45, 95% CI = 0.27 to 0.75) ( Table 2) . Women who had a sister with breast cancer before the index age or reported BRCA testing appeared 29% to 39% less likely to complete five years of tamoxifen, although these estimates did not meet the threshold for statistical significance. For every percentage point increase in BCRAT score, the odds of completing five years of tamoxifen increased by 7% (OR = 1.07, 95% CI = 1.00 to 1.15). Age at tamoxifen initiation, race, smoking, and menopausal status were not statistically significantly associated with discontinuation (Table 2) . Five-year discontinuation rates across calendar years are provided in Supplementary Table 1 (available online) .
Few women reported stroke (three tamoxifen users, four nonusers), TIA (eight tamoxifen users, 22 nonusers), or uterine/endometrial cancer (two tamoxifen users, three nonusers) after the index age. Tamoxifen users were 49% more likely (95% CI = 1.05 to 2.11) to report cataract (55 tamoxifen users, 179 nonusers) compared with nonusers; cataract diagnosis was not statistically significantly related to discontinuation before five years (data not shown).
Discussion
In our sample of 788 women who used tamoxifen for breast cancer prevention outside of a clinical trial from 1986 to 2009, approximately one in five tamoxifen users had no evidence that the benefits were likely to exceed the risks. Absence of expected benefit was most pronounced for older women, African Americans, and those with an intact uterus. A 2011 update to the risk-benefit tables (20) has recently been included in the USPSTF (8), American Society of Clinical Oncology (ASCO) (7) , and the NCCN (21) Breast Cancer Risk Reduction guidelines. Dissemination of the risk-benefit tables will expand the tools available to providers for counseling women about the potential value of breast cancer chemoprevention.
In our analysis, 50% of tamoxifen users were premenopausal. The risk-benefit index is more uniformly favorable for women younger than 50 years (16) , and tamoxifen remains the only FDA-approved chemoprevention agent for premenopausal women. Recent trials of aromatase inhibitors (23, 24) show important benefits for breast cancer prevention; however, their use is limited to postmenopausal women. Until alternative therapies for premenopausal women become available, tamoxifen will continue to have an important role in breast cancer primary prevention.
A recent systematic review of studies examining decisionmaking surrounding tamoxifen use concluded that higher perceived breast cancer risk increased willingness to consider tamoxifen for prevention, but few other characteristics have been identified (25) . Factors associated with actual tamoxifen use may differ from those related to hypothetical decision-making. In our data, tamoxifen users were more likely than nonusers to report non-Hispanic white race, never using unopposed estrogens, stronger family histories of breast cancer, higher BCRAT scores, and worse general health status. We observed no statistically significant association with education, smoking status, or bilateral oophorectomy. These findings differ from studies that reported greater willingness to use tamoxifen among women who were less educated (26), used postmenopausal hormones (10), smoked (10), or had intact ovaries (27) and no association with general health or race (10, 11, 28) . Three studies reported no association between BCRAT scores greater than or equal to vs less than 1.7 and tamoxifen-use (10, 11, 13) , while our analysis and one other (12) observed positive associations using continuous BCRAT scores.
Discontinuation of tamoxifen before the recommended five years (46%) was somewhat greater than the 24% to 36% nonadherence reported in prevention trials (29) . However, it is closely aligned with a recent metaregression estimate of 47.2% five-year discontinuation of tamoxifen as adjuvant endocrine therapy ( [30] , reviewed in [31] ). Women who reported a family history of breast cancer, BRCA1/2 testing, or positive mutation status appeared less likely to complete five years of tamoxifen. Information on the efficacy of tamoxifen for chemoprevention among BRCA1/2 carriers is still limited based on small numbers of carriers in the NSABP P-1 trial (32). Race and smoking status were not statistically significantly associated with tamoxifen discontinuation in our analysis. However, the direction of the estimates was consistent with lower completion rates reported among minority race women and current smokers in the prevention trials (33, 34) . In our sample, age was also not statistically significantly associated with tamoxifen discontinuation, although there was a suggested U-shaped association with the youngest and oldest women less likely to complete five years. Age older or younger than 48 years was not associated with article compliance in the IBIS-1 prevention trial (33); however, women age 60 years and older had lower compliance in the NSABP P-1 trial (34) .
Limitations of this analysis include not having information on pulmonary embolism and deep vein thrombosis for subject selection; however, we excluded women who had other conditions that could contraindicate tamoxifen use. Some characteristics, such as BRCA1/2 testing and biopsy history, were assessed at enrollment rather than index age. However, the matched design ensured that equal time had elapsed since the index age and enrollment. Matching on age prohibited evaluation of the association between age and tamoxifen use. In our sample, 5% of tamoxifen users were excluded for medical history of cataract, stroke, TIA, uterine or endometrial cancer as of the age tamoxifen use was initiated. Our a priori restriction to women who had no known contraindicating medical conditions prior to the index age precluded us from evaluating associations between these conditions and tamoxifen initiation.
We relied on self-reported information on tamoxifen use for breast cancer prevention and clinical trial participation, which has potential to introduce misclassification if women do not provide accurate reports. Although validation data are unavailable for the current study, previous reports have demonstrated 90% to 94% agreement between self-reported tamoxifen use and medical records in the treatment context (35, 36) . Validation data for trial participation and information on the trial outcomes (ie, breast cancer prevention) were not available.
Tamoxifen also has other indications, including ovulation induction (37) , retroperitoneal fibrosis (38) , bipolar disorder (39), and osteoporosis prevention and treatment. In our sample, * Odds ratio and 95% confidence interval among 555 women who reported formerly using tamoxifen (n = 515) or currently using tamoxifen and starting five or more years before study enrollment (n = 40). BCRAT = Breast Cancer Risk Assessment Tool; CI = confidence interval; N/A = not applicable; OR = odds ratio. † Mutually adjusted for other variables in the table except BCRAT score (a composite variable) or BRCA1/2 mutation testing or carrier status (because of small sample sizes). ‡ Adjusted for smoking status, menopausal status, and raloxifene use. § Among women who reported undergoing BRCA1/2 testing.
article osteoporosis diagnosis and raloxifene use were not associated with tamoxifen initiation, although tamoxifen users were more likely to have had a bone density scan within the last 24 months. Raloxifene was approved for primary prevention of breast cancer in 2007 (40) ; the majority of study subjects were enrolled prior to this date. Raloxifene use after tamoxifen was associated with early discontinuation, potentially because of the availability of an alternative preventive therapy. Ninety-seven women reported starting tamoxifen prior to FDA approval; however, based on the highly favorable risk-benefit profiles of these women (Supplementary Table 1 , available online) and overlap with the recruitment years for the prevention trials (initiated in 1990 [4] [5] [6] ), we included them as off-label use. Lastly, our analysis was nested within a family-based cohort study and may not represent women at high risk of breast cancer because of other factors.
The Sister Study, a large cohort of women with a family history of breast cancer, provided a unique opportunity to evaluate tamoxifen use for chemoprevention outside of a clinical trial. Our findings suggest that although the majority of women who use tamoxifen for breast cancer prevention are likely to benefit, care should be directed toward evaluating risk-benefit profiles among women who are older, have an intact uterus, and are African American.
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